

To

Date: 29<sup>th</sup> April, 2023

**The Corporate Relations Department,  
BSE Limited,  
Phiroze Jeejeebhoy Towers,  
Dalal Street,  
Mumbai-400001.**

Dear Sir(s),

**Sub: Conversion of Warrants and Allotment of Equity shares**

**Ref: Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("Listing Regulations")**

**Scrip Code: 524636 | Scrip Symbol: OXYGENTAPH**

\*\*\*\*\*

We wish to inform you that, the Board of Directors of Oxygenta Pharmaceutical Limited (formerly known as S.S. Organics Ltd.) at its meeting held on 29<sup>th</sup> April, 2023, has approved the conversion of warrants into Equity shares pursuant to exercise of option attached to convertible warrants by the warrant holders & accordingly allotted 85,80,700 (Eighty-Five Lakhs Eighty Thousand and Seven hundred) fully paid-up Equity shares of a face value of Rs. 10/- each to the following warrant holders, under Promoter and Non-Promoter category at a price of Rs. 15/- (Rupees Fifteen only) per Equity share, being the price not less than the price determined in accordance with the Chapter V of SEBI (ICDR) Regulations, 2018.

<b>S. No</b>	<b>Name of the allottee</b>	<b>No of Equity shares allotted</b>
1	K Raghavender Rao	8,00,000
2	Sravani Reddy Gantla	44,87,000
3	Vustala Pushpalatha	30,00,000
4	Nikhil Reddy Pasya	2,93,700
<b>Total</b>		<b>85,80,700</b>

Further, the aforesaid allottees had intimated the Company exercising their rights to convert the convertible warrants into Equity shares and have paid the full subscription money for issue and allotment of Equity shares.

Further, the Equity shares allotted as above shall rank pari-passu in all respects including with respect to dividend and voting rights with the existing equity shares of the Company and shall be locked-in pursuant to the provisions of Regulation 167 of the SEBI (ICDR) Regulation, 2018.

Accordingly, the issued, subscribed, and paid-up capital of the Company has increased to Rs. 30,72,70,000/- (Rupees Thirty Crore Seventy-Two Lakhs and Seventy thousand only) divided in to 3,07,27,000 (Three crore Seven lakhs Twenty -Seven thousand) equity shares of face value of Rs. 10/- each (Rupees Ten only) with effect from 29<sup>th</sup> April, 2023.



The said equity shares are going to be listed on BSE Limited.

Pursuant to the Shareholder's resolution dated 23<sup>rd</sup> March, 2023, the Company issued 1,28,37,200 (One crore twenty-eight lakh thirty seven thousand and two hundred) convertible warrants, out of which 85,80,700 (Eighty Five Lakhs Eighty Thousand and Seven hundred) were converted into fully paid equity shares on 29<sup>th</sup> April, 2023 and balance 42,56,500 (Forty Two Lakhs and Fifty Six Thousand and Five hundred) are pending for exercising of an option attached to convertible warrants.

Kindly take the above information on record and acknowledge.

Thanking you

**For Oxygenta Pharmaceutical Limited**  
(Formerly known as S.S. Organics Ltd.)

**Vankineni Sai Sudhakar**  
Managing Director  
DIN: 00733001

---

**OXYGENTA PHARMACEUTICAL LIMITED** (Formerly known as S.S ORGANICS LIMITED)

*(An ISO 9001:2015, ISO 14001 : 2015 and OH&S ISO 45001:2018 Certified Company)*

REGD. OFF & FACTORY: Sy. No. 252/1, Aroor (V), Sadashivpet (M), Sangareddy (Dist) – 502 291, Telangana, INDIA.

Tel: (08455) 250080, Fax: 08455-250090

Corp. Office: Plot No.43, Sy. No. 55 to 58, The Park View, 1st Floor, Lumbini Avenue, Gachibowli, Hyderabad – 500 032.

E-Mail id: [cs@oxygentapharma.com](mailto:cs@oxygentapharma.com), [info@oxygentapharma.com](mailto:info@oxygentapharma.com). Website: [www.oxygentapharma.com](http://www.oxygentapharma.com)

CIN: L24110TG1990PLC012038



**Disclosure under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/CMD/4/2015 dated September 9, 2015 – Conversion of warrants and allotment of Equity shares**

<b>Particulars</b>	<b>Details</b>
Type of Securities proposed to be issued (viz. equity shares, convertibles etc.)	Equity shares issued upon exercise of the convertible warrants outstanding
Type of issuance (further public offering, rights issue, depository receipts (ADR/GDR), qualified institutions placement, preferential allotment etc.)	Equity shares issued and allotted upon exercise of the warrants which were issued by way of Preferential allotment pursuant to the Shareholder's approval vide EGM dated 23 <sup>rd</sup> March, 2023
Total number of Securities proposed to be issued or the total amount for which the securities will be issued (approximately)	Total No of Securities issued and allotted: 85,80,700 Equity shares of Rs. 10/- each fully paid at the ratio of 1:1 – One equity share for every one warrant exercised at a price of Rs. 15/- per share (including premium of Rs.5/- each), aggregating to an amount of Rs. 12,87,10,500/-
Names of the Investors	<ol style="list-style-type: none"> <li>1. Mr. K Raghavender Rao,</li> <li>2. Mrs. Sravani Reddy Gantla,</li> <li>3. Mrs. Vustala Pushpalatha</li> <li>4. Mr. Nikhil Reddy Pasya</li> </ol>
Post allotment of Securities – outcome of the subscription, issue price / allotted price (in case of convertibles), number of investors	<p>Allotment of 85,80,700 equity shares of face value of Rs. 10/- each fully paid up at a premium of Rs. 5/-, at an issue price of Rs. 15/- per share, aggregating to an amount of Rs. 12,87,10,500/- at the ratio of 1:1 – One equity share for every one warrant exercised, to a 4 (four) individual investors as follows:</p> <ol style="list-style-type: none"> <li>1. Mr. K Raghavender Rao,</li> <li>2. Mrs. Sravani Reddy Gantla,</li> <li>3. Mrs. Vustala Pushpalatha</li> <li>4. Mr. Nikhil Reddy Pasya</li> </ol>
In case of Convertible – intimation on conversion of securities or on lapse of the tenure of the instrument	Intimation on conversion of securities i.e., exercise of 85,80,700 warrants into 85,80,700 fully paid-up equity shares of Rs. 10/- each fully paid up.

**For Oxygenta Pharmaceutical Limited**

(Formerly known as S.S. Organics Ltd.)

**Vankineni Sai Sudhakar**

Managing Director

DIN: 00733001